Yichang Humanwell Pharmaceutical Co., Ltd., China
9
2
2
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 9 trials
100.0%
+13.5% vs industry average
44%
4 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
Step 1 of A Two-step Trial to Evaluate the Effectiveness and Safety of Remimazolam Besylate for Sedation in ICU Patients
Role: collaborator
Intravenous Hydromorphone for the Treatment of Acute Pain
Role: collaborator
The Evaluation of the Effectiveness and Safety of Nalbuphine Hydrochloride Injection for Analgesia in ICU Patients: A Multicenter, Randomized, Single-blinded, Parallel, Two-step Trial
Role: collaborator
Step 2 of A Two-step Trial to Evaluate the Effectiveness and Safety of Remimazolam Besylate for Sedation in ICU Patients
Role: collaborator
PK/PD Properties and Safety of Remazolam Besylate for Injection in ICU Patients With Impaired Renal Function
Role: collaborator
Effect of Rematazolam Besylate, Propofol, and Sevoflurane Perioperative Sedation on Incidence of Emergence Agitation and Hemodynamics in Patients Undergoing Laparoscopic Abdominal Surgery
Role: collaborator
The Availability and Safety Study of Remimazolam Besylate for Injection on Sedation of ERAS Patients
Role: collaborator
Impact of CYP3A4*1G Polymorphism on Non-analgesic Effects of Fentanyl in Chinese Han Patients
Role: collaborator
the Research of Analgesia and Sedation Effect of Remifentanil on ICU Short Operation
Role: collaborator
All 9 trials loaded